RxDoctor Payments Data

Ellen Cleland, MD

Family Medicine · Chattanooga, TNNPI 1124525423

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,357 of the $37,644 with a category attached, or 93.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 94.1% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $23,963, more than ten times the $98 reported in 2023. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,644in general payments, 2019–2025

Across 89 payments — averaging $422.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$35K
  • Novo Nordisk$547
  • Xeris Pharmaceuticals, Inc.$290
  • Axsome Therapeutics, Inc.$168
  • Bard Peripheral Vascular, Inc.$146
  • Otsuka America Pharmaceutical, Inc.$140
  • plus $947 from 18 others

What the payments were for

  • Consulting fees$35,35794%
  • Food & beverage$2,2876%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,644 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$21,960
Medicare patients
53
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$26,544
OzempicSemaglutide19$21,104
EliquisApixaban17$19,160
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,068
Potassium Chloride23$922
Losartan Potassium59$918
Gabapentin52$822
Omeprazole50$764
Atorvastatin Calcium59$748
Duloxetine Hcl23$638
Pravastatin Sodium27$609
Rosuvastatin Calcium38$574
Levothyroxine Sodium56$545
Valsartan12$544
Albuterol Sulfate HfaAlbuterol Sulfate25$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$112$26,54422 claims
Novo NordiskOzempic$547$21,10419 claims
PfizerEliquis$15$19,16017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →